Wintrust Investments LLC Buys 177 Shares of Edwards Lifesciences Co. (NYSE:EW)

Wintrust Investments LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 2,384 shares of the medical research company’s stock after acquiring an additional 177 shares during the quarter. Wintrust Investments LLC’s holdings in Edwards Lifesciences were worth $176,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of EW. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC raised its position in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc bought a new stake in Edwards Lifesciences during the fourth quarter worth $46,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

EW stock opened at $68.52 on Thursday. The stock’s 50 day simple moving average is $71.92 and its 200 day simple moving average is $70.34. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market capitalization of $40.28 billion, a PE ratio of 9.83, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on EW. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Piper Sandler raised their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Canaccord Genuity Group upped their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Citigroup raised their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Evercore ISI decreased their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and a consensus price target of $79.95.

Insider Activity

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,303 shares of company stock valued at $3,255,356 over the last three months. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.